文献速递眼底病与葡萄膜炎

Brolucizumab治疗增殖性糖尿病视网膜病变:CONDOR随机临床试验

Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2026-01-01

CONDOR是一项96周、2臂、单盲、多中心、3期随机临床试验,在16个国家152个中心开展,纳入689例未接受过全视网膜光凝(PRP)的增殖性糖尿病视网膜病变(PDR)患者。结果显示,brolucizumab 6 mg在第54周最佳矫正视力(BCVA)变化上非劣效且优于PRP(差异4.4个字母,95%CI 2.4-6.4,P<.001),且更高比例患者无PDR活动。brolucizumab组眼内炎症(含视网膜血管炎)发生率为5.2%,高于PRP组的0.6%。

要点

  • brolucizumab 6 mg在第54周BCVA变化上非劣效且优于PRP,差异4.4个字母。
  • brolucizumab组63.6%患者第54周无PDR,显著高于PRP组的22.4%。
  • brolucizumab组眼内炎症(含视网膜血管炎)发生率5.2%,PRP组为0.6%。

核心结论

  • 在CONDOR随机临床试验中,brolucizumab在保持视力方面优于PRP,可能成为PDR患者PRP单药治疗的可行替代方案。

研究设计与样本

  • CONDOR是一项96周、2臂、单盲、多中心、3期随机临床试验,在16个国家152个中心开展。
  • 共纳入689例糖尿病患者,随机1:1分配至brolucizumab 6 mg组(n=347)或PRP组(n=342),572例完成第54周访视。
  • 纳入标准为诊断为PDR且研究眼未接受过PRP治疗的患者。

主要发现

  • 第54周BCVA最小二乘均值(SE)变化:brolucizumab组0.2(0.72)个字母,PRP组-4.2(0.73)个字母,差异4.4(95%CI 2.4-6.4,P<.001)。
  • 第54周无PDR的患者比例:brolucizumab组187例(63.6%),PRP组65例(22.4%),差异39.4(95%CI 32.0-46.8,P<.001)。
  • 眼不良事件发生率:brolucizumab组119例(34.3%),PRP组168例(49.1%)。
  • 眼内炎症(含视网膜血管炎)发生率:brolucizumab组18/347例(5.2%),PRP组2/342例(0.6%)。

关键数值与推荐

  • brolucizumab组给予3次负荷剂量每6周一次,随后每12周一次,第48周起可根据疾病活动度每次延长6周直至24周。
  • PRP组在至第12周内接受1至4次治疗,之后按需追加PRP。
  • 主要结局为第54周BCVA较基线变化;次要结局包括DR进展、预防中心受累性糖尿病黄斑水肿、DR严重程度评分变化及安全性。

临床怎么用

  • 对于未接受过PRP的PDR患者,brolucizumab 6 mg可作为PRP单药治疗的替代选择,以更好地保持视力并促进PDR消退。
  • 使用brolucizumab需警惕眼内炎症(含视网膜血管炎)风险,本研究中发生率为5.2%,应进行监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: CONDOR (Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy) is a large-scale, company-sponsored randomized clinical trial to assess the unique 6-week (loading) and 12-week (maintenance) brolucizumab dosing regimen in proliferative diabetic retinopathy (PDR). OBJECTIVE: To assess the efficacy and safety of brolucizumab, 6 mg, compared with panretinal laser photocoagulation (PRP) in eyes with PDR. DESIGN, SETTING, AND PARTICIPANTS: CONDOR is a 96-week, 2-arm, single-masked, multicenter, phase 3 randomized clinical trial conducted across 16 countries at 152 sites. Data were analyzed from December 4, 2020 (first participant first visit), to October 30, 2023 (cutoff date). Patients with diabetes and PDR diagnosis and no previous PRP treatment in the study eye were eligible for inclusion. INTERVENTION: Patients randomized to receive brolucizumab, 6 mg, received 3 loading doses every 6 weeks, followed by every 12 weeks, with the option from week 48 onward to extend the treatment interval by 6 weeks at a time up to 24 weeks based on disease activity. Patients randomized to PRP received treatment in 1 to 4 sessions up to week 12, followed by additional PRP treatment as needed. MAIN OUTCOMES AND MEASURES: The primary outcome measure was change from baseline in best-corrected visual acuity (BCVA) at week 54. Secondary outcomes included change in DR progression, prevention of center-involved diabetic macular edema, change in Diabetic Retinopathy Severity Score levels, and safety. RESULTS: A total of 689 participants were randomized in a 1:1 ratio to brolucizumab, 6 mg (n = 347), or PRP (n = 342), and 572 randomized participants completed the week 54 visit. Mean (SD) patient age was 53.9 (11.39) years, 276 patients (40.1%) were female, and mean (SD) BCVA (letter score) at baseline was 77.1 (10.55) (Snellen equivalent, 20/32). Brolucizumab, 6 mg, was noninferior and superior to PRP for BCVA change at week 54 (least-squares mean [SE] change in letter score: 0.2 [0.72] vs -4.2 [0.73]; difference, 4.4; 95% CI, 2.4-6.4; P < .001). A higher proportion of patients receiving brolucizumab, 6 mg, had no PDR at week 54 vs patients receiving PRP (187 [63.6%] vs 65 [22.4%]; difference, 39.4; 95% CI, 32.0-46.8; P < .001). Ocular adverse events were reported in 119 patients (34.3%) and 168 patients (49.1%) in the brolucizumab, 6 mg, arm and PRP arm, respectively. The rate of intraocular inflammation, including retinal vasculitis, was 18 of 347 patients (5.2%) in the brolucizumab, 6 mg, arm and 2 of 342 patients (0.6%) in the PRP arm. CONCLUSIONS AND RELEVANCE: In the CONDOR randomized clinical trial, brolucizumab was superior to PRP in preserving visual acuity and may be a viable treatment alternative to PRP monotherapy for patients with PDR. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04278417.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wolf S, Chen Y, Li X, et al. Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial. JAMA Ophthalmol. 2026. PMID: 42024409. doi:10.1001/jamaophthalmol.2026.1008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。